drugset
drugset / Trial / NCT04338997

PK Study in Patients With Parkinson's Disease With IZD174

NCT04338997 ↗

Phase 1 Withdrawn Inflazome UK Ltd
NaSingle-groupOpen-labelBasic science

Summary

Single center, open-label, intra-individual dose-escalation study in subjects with mild/moderate Parkinson's Disease

Timeline

Start
2020-10
Primary completion
2020-11
Completion
2020-12

Outcome

Outcome not reported

Stopped (Business): “Strategic decision by Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject Inzomelid Small molecule — Oral

Indications

Parkinson disease